Pfizer will buy NextWave Pharma for up to $700M

October 22, 2012

(AP)—Pfizer said Monday it will buy NextWave Pharmaceuticals Inc., a company that makes a liquid attention deficit hyperactivity disorder drug, in a deal worth as much as $700 million.

The approved NextWave's drug Quillivant XR in September, and the once-per-day drug is expected to be in pharmacies in January.

made a $20 million option payment to Cupertino, California-based NextWave in the second quarter to establish a merger agreement. The company will pay $255 million when the deal closes, and agreed to pay NextWave another $425 million based on sales milestones.

Pfizer said about 9.5 percent of children have received a diagnosis of ADHD at some point, and around 4 percent of adults have the condition.

NextWave is also developing extended release chewable tablets using the same drug. It has an advanced-stage study of the tablets in process, and aims to submit the product for approval next year.

Pfizer expects the deal to close during the fourth quarter, subject to regulatory approval.

Shares of . slipped a penny to $25.75 in premarket trading.

Explore further: Pfizer drug found with serious side effect

shares

Related Stories

Pfizer drug found with serious side effect

November 1, 2006

U.S. pharmaceutical company Pfizer Inc. says clinical trials of its heart medication torcetrapib suggest the drug has a potentially serious side effect.

Pfizer will buy King Pharmaceuticals for $3.6B

October 12, 2010

(AP) -- Pfizer Inc. said Tuesday it will buy a company specializing in pain drugs in a $3.6 billion deal meant to shore up the portfolio of the world's largest drug company.

Citing liver damage, Pfizer withdraws Thelin

December 10, 2010

(AP) -- Pfizer Inc. said Friday it is pulling its blood pressure drug Thelin off the market and stopping all clinical trials because the drug can cause fatal liver damage.

FDA clears Pfizer drug for advanced kidney cancer

January 27, 2012

(AP) -- The Food and Drug Administration has approved a new Pfizer drug for patients with advanced kidney cancer that has spread to other parts of the body despite treatment with at least one previous drug.

AT&T goes on spectrum shopping binge

August 2, 2012

(AP) — AT&T Inc. has gone on a shopping spree for wireless spectrum, striking three separate deals that should let it increase its capacity for wireless broadband.

Recommended for you

Non-addictive painkiller shows promise in animal trials

August 30, 2016

(HealthDay)—Preliminary research in monkeys suggests that a new medication might be able to provide pain relief similar to opioid drugs such as OxyContin, but without the same potential for addiction or serious side effects.

Mylan launching cheaper, generic version of EpiPen

August 29, 2016

The maker of EpiPens will start selling a cheaper, generic version of the emergency allergy shots as the furor over repeated U.S. price hikes continues—and looming competition threatens its near-monopoly.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.